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Abstract 
Lipoprotein lipase (LPL) is a lipolytic enzyme involved in catalyzing hydrolysis of 
triglycerides (TG) in chylomicrons and very low-density lipoprotein (VLDL) particles. 
Over the last decade, increasing attention has been paid to the clinical significance of 
measuring serum LPL protein mass without heparin injection to the study subjects. In 
earlier studies, this marker was utilized to classify LPL deficient subjects, which is an 
extremely rare metabolic disorder with a frequency of one in one million. Later, 
researchers paid more attention to the clinical significance of measuring this parameter 
in more common metabolic disorders.  Studies have shown that pre-heparin plasma or 
serum LPL mass has significant relationships with serum lipids and lipoproteins, 
visceral fat area, insulin resistance, and even the development of coronary 
atherosclerosis in cross-sectional studies, although this might be a metabolic surrogate 
marker with almost no catalytic activities, which does not appear to be involved in 
catalyzing hydrolysis of TG in TG-rich lipoproteins. Recently, a prospective study has 
demonstrated that low serum LPL concentration predicts future coronary events. 
Taken together, we suggest that pre-heparin LPL mass in plasma or sera 
provide us with useful and important information on the development of metabolic 





Lipoprotein lipase (LPL) plays a central role in lipoprotein metabolism by catalyzing 
hydrolysis of triglycerides (TG) in chylomicrons and very low-density lipoprotein 
(VLDL) particles [1-3]. Since a decade ago, it has been noted that besides its function of 
catalytic enzyme, LPL functions as a mediator facilitating binding and/or incorporation 
of series of lipoproteins through either lipoprotein receptors or heparan sulfate 
proteoglycans [4-8] into several lines of cells. LPL is synthesized and secreted in 
adipocytes, muscle cells, cardiomyocytes and macrophages [3], which is transferred to 
heparan-sulfate on the luminal surface of the endothelial cells in vessels through 
unknown mechanism [9-11].  
In clinical studies, post-heparin plasma (PHP) is usually used as a material for the 
measurement of LPL mass and activity. From the last decade, however, several groups 
of researchers [12-19] have shown the clinical significance of measuring LPL protein 
mass in plasma or sera by an enzyme-linked immunosorbent assay (ELISA) without 
heparin injection (simply put as serum or plasma LPL mass). In earlier studies, 
researchers applied the measurement of plasma or serum LPL mass to detailed analysis 
and characterization of type 1 hyperlipidemia (HLP) [16,17]. In 1989, Auwerx et al. 
[16] proposed that type 1 HLP be classified into three subtypes according to the amount 
of LPL mass in pre- and post-heparin plasma. In 1990, Kern et al. [17] conducted 
detailed analysis of LPL protein in pre- and post-heparin plasma from both normal 
subjects and type 1 HLP. In recent years, the measurement of plasma or serum LPL 
mass has been conducted to clarify the pathophysiology of more common metabolic 
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disorders. Tornvall et al. [13,15] have studied the correlation between lipoproteins and 
plasma LPL mass from men before the age of 45 years with coronary heart disease and 
from age-matched controls, and found that there was a strong positive correlation 
between plasma LPL mass and HDL-C levels as well as weak negative relations to 
VLDL-TG in the patients. The study by Watanabe et al. [14] has shown that serum LPL 
mass is lower in conditions in which TG catabolism is disturbed, such as 
hypertriglyceridemia and individuals with increased remnant lipoproteins.  
In this review, we focus on recent advances in the research on clinical 
significance of measuring plasma or serum LPL mass without heparin-injection into 
study subjects, based on several clinical findings reported in the last decade.  
2. Biochemical Properties of Pre-Heparin LPL 
It has been shown that LPL activity in plasma increased about as high as 170-fold, 
whereas LPL mass increased only about 9-fold after heparin injection [13]. Most of the 
LPL protein in plasma elutes as an early peak from heparin-Sepharose, corresponding to 
the position for inactive monomeric LPL and is demonstrated to be full-length LPL, 
which is bound to plasma lipoproteins [12]. Thus, it is unlikely that the measured 
plasma LPL mass directly contributes to catalyzing hydrolysis of triglycerides in 
TG-rich lipoproteins in the plasma. Several researchers have shown that this inactive 
protein may act as a ligand targeting lipoproteins for binding to cell surfaces and 
receptors [18].  
3. Correlation of Serum LPL to Post-Heparin Plasma (PHP) LPL Mass  
It has been reported that serum LPL mass had a positive relation with PHP- 
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LPL mass [14,19,20], although the degree of the relation appeared to differ among the 
reports.  It should be noted that Hirano et al. [20] have shown that the delta LPL 
concentration was strongly related to the PHP-LPL concentration (r =.965, P </=.0001), 
but not to the serum LPL mass, suggesting that the weak correlation between serum 
LPL and PHP-LPL levels was attributable to contamination of PHP by pre-existing 
LPL. 
4. Relationship Between Plasma LPL Mass and Intra-Abdominal Visceral Fat  
It is generally recognized that individuals with obesity have high prevalence 
of complications, such as impaired glucose tolerance, hyperlipidemia, and hypertension 
However, it is also true that the degree of obesity does not necessarily account for the 
severity of these disorders [21]. Studies have suggested that fat distribution and 
abdominal fat accumulation are good predictors of the development of coronary heart 
disease [22-24]. Moreover, intra-abdominal visceral fat accumulation is shown to be 
associated with insulin resistance [25]. Several clinical studies were conducted for 
analyzing the relationship of LPL mass, either in pre-heparin plasma (or serum) or PHP, 
to visceral fat accumulation. We and other groups have reported that intra-abdominal 
visceral fat area assessed by CT at umbilical level had an inverse relationship to LPL 
mass and activity in PHP [26-28].  Similar results were obtained on the association 
between intra-abdominal visceral fat and pre-heparin LPL mass [19] by recruiting a 
total of 58 subjects comprising 50 hyperlipidemic and 8 normolipidemic subjects.  
In that study, plasma LPL mass had an inverse relationship to intra-abdominal visceral 
fat area, but did not show any statistically significant correlation to subcutaneous fat 
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area.  Multiple regression analysis performed with plasma LPL mass as a dependent 
variable, and visceral fat area and BMI as independent variables revealed that the 
visceral fat area had an inverse relation to plasma LPL mass, independent of BMI.  
We have conducted the receiver operator characteristic (ROC) analysis for LPL 
concentration to predict the presence of intra-abdominal visceral fat area>100cm2  
(Fig.1). This finding suggests that the optimal cut off point of serum LPL mass for 
predicting visceral fat accumulation could be around 40 ng/ml. Furthermore, we also 
subdivided the whole subjects into each gender and found that the optimalcut off point 
of LPL mass for men might be 35 ng/ml rather than 40 ng/ml (Fig.2). 
5. Relationship of serum LPL concentration with lipoproteins and apolipoproteins  
  We have shown that plasma LPL mass correlated positively with serum HDL-C 
level and inversely with serum TG level, but did not significantly correlate with 
low-density lipoprotein (LDL)-C [19]. Other group in Japan has reported similar results 
for 377 Japanese individuals who underwent annual health examinations [14].  
 The study by Tornvall et al. [13] has shown this association existed in 61 men who had 
suffered myocardial infarction before the age of 45 years. For the association with 
serum apolipoproteins, plasma LPL mass had a positive correlation with serum 
apolipoprotein (apo) A-I, but not apo B or E.  Furthermore, it has been shown that 
serum LPL correlated inversely with TG, remnants, and insulin resistance and positively 
with HDL cholesterol and LDL size in164 Japanese hyperlipidemic subjects [20]. This 
finding has been confirmed by the recent report [29] showing a strong positive 
correlation between serum LPL concentration vs. LDL and HDL sizes measured by 
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nuclear magnetic resonance.  These observations support the association of a high 
serum LPL concentration with a beneficial lipid profile.  
6. Serum LPL Mass in Type 2 Diabetes Mellitus 
  A study has shown that serum LPL concentration was considerably lower in type 2 
diabetic patients (n=40) than in non-diabetic healthy controls, and had an inverse 
relation to HbA1c in diabetic individuals [30]. For 15 subjects among them, they 
investigated the effect of insulin treatment on serum LPL mass and plasma glucose 
levels, and found that serum LPL mass increased significantly at week 4 on insulin 
treatment, with concomitant reduction in fasting blood glucose level.  We analyzed 
gender difference in plasma LPL mass and other metabolic parameters from Japanese 
type 2 diabetic subjects after adjusting for age, BMI, and HbA1c [31]. The men group 
showed a higher serum TG and lower HDL-C levels along with lower plasma LPL mass 
than did women. Troglitazone, an insulin sensitizer and now out of market in Japan, was 
reported to cause an increase in pre-heparin LPL mass [32], which is consistent with our 
study showing this agents increased LPL mass in PHP [33].    
7. Serum LPL mass in acute inflammation 
  We had a diabetic woman with severe foot gangrene, who had a markedly low 
HDL-C and serum LPL mass [34]. Serum LPL mass and serum HDL-C returned to 
almost normal level during treatment of her diabetes and gangrene with insulin and 
anti-biotics. Serum C-reactive protein levels had an inverse relationship to serum LPL 
mass, suggesting that in acute inflammation, the production of LPL in adipocytes or 
muscle tissue is highly inhibited. Serum C-reactive protein levels also showed an 
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inverse relation to plasma glucose levels, although to a lesser degree.  
8. Serum LPL concentration and insulin resistance 
The recent report by Hanyu et al. [35] has indicated that serum LPL mass 
correlated significantly with insulin sensitivity analyzed by minimal model, which is 
applied to all of the subjects they studied regardless of whether the subjects had normal 
glucose tolerance, impaired glucose tolerance, and diabetes. Also, serum LPL mass 
correlated negatively with HOMA-R and fasting IRI.  
9. Serum LPL concentration and serum adiponectin levels 
Recently, it has been shown that LPL activities in post-heparin plasma were positively 
associated with serum adiponectin levels [36-38].  More recently, Saiki et al [39] 
have reported that in 362 Japanese subjects with metabolic syndrome, the 
correlation coefficient between serum LPL mass and plasma adiponectin was 
high (r=0.562). They also have shown that both serum LPL mass and adiponectin 
correlated positively with HDL-C and inversely with body weight and TG.  Also, 
serum LPL mass and plasma adiponectin decreased with an increase in severity 
of the metabolic syndrome with/without obesity and with/without diabetes.  
10. The Association of Pre-Heparin LPL Mass and the Incidence of Coronary artery 
disease (CAD) 
Hitsumoto et al. [40,41] compared pre-heparin LPL mass in men with angiographically 
determined coronary atherosclerosis versus that in men with normal coronary or healthy 
men. They found that men with coronary atherosclerosis had significantly lower 
pre-heparin LPL mass than did men without coronary atherosclerosis or healthy men.  
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They suggest that serum LPL mass is an independent determinant of incidence[40] or 
severity[41] of coronary artery disease even after adjustments of a number of metabolic 
parameters, including serum triglycerides and HDL-C.  
11. Prospective associations between serum LPL concentration and risk for future 
CAD 
To demonstrate whether or not low LPL mass is the result or the cause of coronary heart 
disease, it is essential to conduct a prospective study on the association of these two 
markers. Recently, Rip et al. [29] determined serum LPL concentrations from men and 
women in the EPIC-Norfork population cohort who developed fatal or nonfatal CAD 
during 7 years of follow-up. Subjects with highest LPL concentration quartile had a 
34% lower risk for future CAD compared with those in the lowest quartile. This effect 
remained significant after adjustment for blood pressure , diabetes, smoking, body mass 
index, and LDL-C but not significant after additional adjustment for TG or HDL-C. 
Their results suggest that high LPL concentrations may be athero-protective through 
associations with decreased TG levels and increased HDL-C levels.  In this regard, 
their study did not appear to be consistent with the above-mentioned cross-sectional 
study by Japanese investigators suggesting that serum LPL mass could be risk factor for 
CAD, independent of TG and HDL-C.  In addition to the relation of serum LPL mass 
to the incidence of coronary heart disease, we have recently found that in Japanese 
hyperlipidemic subjects, serum LPL mass showed an inverse association with average 
intima-media thickness of right and left common carotid arteries assessed with 
ultrasonography following previously reported method [42], 
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independent of age,gender, body mass index, LDL-C,HDL-C and TG in a multiple 
regression analysis, (Table 1). This finding suggests that serum LPL mass predict the 
development of atherosclerosis in carotid artery as well as in coronary artery. 
12. Effects of Several Lipid-Lowering Agents on serum LPL Mass 
It has been shown that bezafibrate, a lipid lowering compound known to cause 
a reduction in serum TG level with increase in HDL-C levels [43], has produced a 
considerable increase in serum LPL mass in hypertriglyceridemic patients [44]. This 
observation has been in line with the previous reports on the effects of this compound 
on LPL activity in PHP [45,46].  Recently, it has been reported that series of statins, 
such as pravastatins, atorvastatins and pitavastatins may produce a significant increase 
in serum LPL mass after the treatment [47,48]. An in vitro study has shown that that 
pitavastatins increase the expression of LPL mRNA from cultured 3T3 L1 cells [47]. 
Their study appeared to be somehow incompatible with our study showing atorvastatin 
did not produce an increase in pre-heparin LPL mass in hyperlipidemic subjects, despite 
causing a substantial reduction in serum TG level [49]. This might be partly associated 
with the different clinical profile of the study subjects with their study subjects being 
type 2 diabetes having lower serum HDL-C levels at baseline compared with ours. 
We have suggested that the main mechanisms by which atorvastatins produced 
considerable TG reductions may be due to their inhibition of the production and 
secretion of VLDL from the liver.  
13. Concluding remarks 
According to considerable number of evidence above mentioned, measuring pre-heparin 
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LPL mass in plasma or sera provides us with useful information on understanding the 
pathophysiology of several metabolic disorders, such as visceral fat accumulation, 
diabetes mellitus and insulin resistance, which are highly associated with the incidence 
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Figure legends  
 
Figure 1  The  receiver operator characteristic (ROC ) analysis for serum lipoprotein 
lipase mass to predict the presence of intra-abdominal visceral fat area ≧100 cm2 
 
Figure 2  The  receiver operator characteristic (ROC ) analysis for serum lipoprotein 
lipase mass to predict the presence of intra-abdominal visceral fat area ≧100 cm2 
in men (n=33) and women (n=25), separately. 
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 Ln LPL .142 -2.209 .0352
age .004 2.467 .0198
gender .092 .519 .6079
Body mass index .020 -.497 .6228
LDL-C .001 1.608 .1187
HDL-C .003 .224 .8245










 Table 1  A multiple regression analysis with  intima-media thickness of
common carotid artery assessed with  ultrasonography, with age, gender, body
mass index, LDL-C, HDL-C and TG as independent variables
The measurement of intima-media thickness in the common carotid artey was made along a 10 mm long section just
proximal to the carotid bulb. The means of three separately analyzed images was used and average IMT was
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